Identification of novel combined biomarkers in the diagnosis of multiple myeloma

References

• Egan PA, Elder PT, Deighan WI, et al. Multiple myeloma with central nervous system relapse. Haematologica. 2020;105(7):1780–1790.
   PubMed Web of Science ®Google Scholar
• Gerecke C, Fuhrmann S, Strifler S, et al. The diagnosis and treatment of multiple myeloma. Deutsches Arzteblatt International. 2016;113(27-28):470), -+.
   PubMed Web of Science ®Google Scholar
• Fraz MA, Warraich FH, Warraich SU, et al. Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction. Crit Rev Oncol Hematol. 2019;137:18–26.
   PubMed Web of Science ®Google Scholar
• Zamagni E, Tacchetti P, Cavo M. Imaging in multiple myeloma: How? When? Blood. 2019;133(7):644–651.
   PubMed Web of Science ®Google Scholar
• Landgren O, Rajkumar SV. New developments in diagnosis, prognosis, and assessment of response in multiple myeloma. Clin Cancer Res. 2016;22(22):5428–5433.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122–1128.
   PubMed Web of Science ®Google Scholar
• Smith D, Yong K. Advances in understanding prognosis in myeloma. Br J Haematol. 2016;175(3):367–380.
   PubMed Web of Science ®Google Scholar
• Harshman SW, Canella A, Ciarlariello PD, et al. Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers. J Proteomics. 2016;136:89–98.
   PubMed Web of Science ®Google Scholar
• Ting KR, Brady JJ, Hameed A, et al. Clinical utility of C-terminal telopeptide of type 1 collagen in multiple myeloma. Br J Haematol. 2016;173(1):82–88.
   PubMed Web of Science ®Google Scholar
• Mabille C, Ruyssen-Witrand A, Degboe Y, et al. DKK1 and sclerostin are early markers of relapse in multiple myeloma. Bone. 2018;113:114–117.
   PubMed Web of Science ®Google Scholar
• Feng YF, Zhang YX, Wei XF, et al. Correlations of DKK1 with pathogenesis and prognosis of human multiple myeloma. Cancer Biomark. 2019;24(2):195–201.
   PubMed Web of Science ®Google Scholar
• Cavo M, Terpos E, Nanni C, et al. Role of F-18-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International myeloma working group. Lancet Oncology. 2017;18(4):E206–E217.
   PubMed Web of Science ®Google Scholar
• Long SP, Qin Q, Wang YN, et al. Nanoporous silica coupled MALDI-TOF MS detection of Bence-Jones proteins in human urine for diagnosis of multiple myeloma. Talanta. 2019;200:288–292.
   PubMed Web of Science ®Google Scholar
• Foulk B, Schaffer M, Gross S, et al. Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disorders. Br J Haematol. 2018;180(1):71–81.
   PubMed Web of Science ®Google Scholar
• Levin A, Hari P, Dhakal B. Novel biomarkers in multiple myeloma. Transl Res. 2018;201:49–59.
   PubMed Web of Science ®Google Scholar
• Jin Y, Wang J, Ye X, et al. Identification of GlcNAcylated alpha-1-antichymotrypsin as an early biomarker in human non-small-cell lung cancer by quantitative proteomic analysis with two lectins. Br J Cancer. 2016;114(5):532–544.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Westhrin M, Bondt A, et al. Serum protein N-glycosylation changes in multiple myeloma. Biochim Biophys Acta Gen Subj. 2019;1863(5):960–970.
   PubMed Web of Science ®Google Scholar
• Mittermayr S, Le GN, Clarke C, et al. Polyclonal immunoglobulin G N-glycosylation in the pathogenesis of plasma cell disorders. J Proteome Res. 2017;16(2):748–762.
   PubMed Web of Science ®Google Scholar
• Chen J, Fang M, Chen X, et al. N-glycosylation of serum proteins for the assessment of patients with IgD multiple myeloma. BMC Cancer. 2017;17(1):881.
   PubMedGoogle Scholar
• Andrulis M, Ellert E, Mandel U, et al. Expression of mucin-1 in multiple myeloma and its precursors: correlation with glycosylation and subcellular localization. Histopathology. 2014;64(6):799–806.
   PubMed Web of Science ®Google Scholar
• Glavey SV, Manier S, Natoni A, et al. The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma. Blood. 2014;124(11):1765–1776.
   PubMed Web of Science ®Google Scholar
• Tibullo D, Giallongo C, Romano A, et al. Mitochondrial functions, energy metabolism and protein glycosylation are interconnected processes mediating resistance to bortezomib in multiple myeloma cells. Biomolecules. 2020;10(5):696.
   PubMed Web of Science ®Google Scholar
• Jiang S, Chen Y, Wang M, et al. A novel lectin from Agrocybe aegerita shows high binding selectivity for terminal N-acetylglucosamine. Biochem J. 2012;443(2):369–378.
   PubMedGoogle Scholar
• Liu W, Han G, Yin Y, et al. AANL (Agrocybe aegerita lectin 2) is a new facile tool to probe for O-GlcNAcylation. Glycobiology. 2018;28(6):363–373.
   PubMed Web of Science ®Google Scholar
• Jin Y, Yang Y, Su Y, et al. Identification a novel clinical biomarker in early diagnosis of human non-small cell lung cancer. Glycoconj J. 2019;36(1):57–68.
   PubMed Web of Science ®Google Scholar
• Su Y, Ye X, Xu B, et al. CBS homogenization mutation strategy narrows the glycan binding profile of a GlcNAc-specific lectin AANL. Glycobiology. 2020;30(3):159–173.
   PubMed Web of Science ®Google Scholar
• Khan R, Gupta N, Kumar R, et al. Augmented expression of urokinase plasminogen activator and extracellular matrix proteins associates with multiple myeloma progression. Clin Exp Metastasis. 2014;31(5):585–593.
   PubMed Web of Science ®Google Scholar
• Lowenthal MS, Davis KS, Formolo T, et al. Identification of novel N-glycosylation sites at noncanonical protein consensus motifs. J Proteome Res. 2016;15(7):2087–2101.
   PubMed Web of Science ®Google Scholar